Hi Ya'll, I hope you're having a Good Friday night. I came across this gem yesterday and I have to give it a shout out. ObsEva is a unique company, and has lots of potential. They have three drugs currently in pipelines. Its recently broken out and is channeling upward and moving very healthily. I have a price target of $10+. With a long term hold.
Yselty is about to be finished testing. It looks positive and ready to be sold world wide. This product is very good for dealing with uterary fibroids which is very common and has no clear medication to use to solve it.
If y'all can post your own understanding of the significance of these drugs I would appreciate it. I do not fully understand what these drugs do but they seem to be a big deal.
Many analysts have set price targets ranging from $4.00-$28.00 a share. I will link this.
I also hold some shares of Obseva with the same long term vision.
Biotech is a complex field when it comes to trading analysis and taking profit.
This month, we will have the clinical trials results for Ebopripant in phase 2 that will hopefully provide positive results in safety and efficiency. (probabilities are empirical but the most drugs are failing between II-III). However, Ebopripan's indication is clearly an unmet need and would be of a great use for pregnant women struggling when it comes to giving birth.
I believe that in case of clinical trial postponment, the share price will decrease with a line of support at 1.5$.
In case of phase II clearance, the share price will bounce high (min 60%) in the same day where some of your profit must be taken (e.g.selling half of your shares). You can then short sell the share after market speculation is diminishing and close your position on the short term.
Some of your money can be re-invested in other shares while you are impatiently waiting for Yselty to get fast track FDA-approval with hopefully once again positive results by Q4 2021, but I am very optimistic about this product being marketed over the next years.
Analyst recommendation for biotech stocks are usually biased because the valuation results differs whether taking into consideration that each product in the pipeline will provide future positive results in clinical trials.
Sales can be forecasted dencently for Yselty according to the relevant data of how many women are suffering from uterin fibroids in NA and EU and I do think they take it in consideration as well as potential royalties and upfront payments declared directly strengthening corporation's balance sheet in terms of cash flow and marketable securities affecting the stock price.
10-11$ is a more accurate range for a probabale post-valuation according to the several analysts you mentionned, 28$ sounds too fun to be true but who knows ?
I hope you are doing well.
I also hold some shares of Obseva with the same long term vision.
Biotech is a complex field when it comes to trading analysis and taking profit.
This month, we will have the clinical trials results for Ebopripant in phase 2 that will hopefully provide positive results in safety and efficiency. (probabilities are empirical but the most drugs are failing between II-III). However, Ebopripan's indication is clearly an unmet need and would be of a great use for pregnant women struggling when it comes to giving birth.
I believe that in case of clinical trial postponment, the share price will decrease with a line of support at 1.5$.
In case of phase II clearance, the share price will bounce high (min 60%) in the same day where some of your profit must be taken (e.g.selling half of your shares). You can then short sell the share after market speculation is diminishing and close your position on the short term.
Some of your money can be re-invested in other shares while you are impatiently waiting for Yselty to get fast track FDA-approval with hopefully once again positive results by Q4 2021, but I am very optimistic about this product being marketed over the next years.
Analyst recommendation for biotech stocks are usually biased because the valuation results differs whether taking into consideration that each product in the pipeline will provide future positive results in clinical trials.
Sales can be forecasted dencently for Yselty according to the relevant data of how many women are suffering from uterin fibroids in NA and EU and I do think they take it in consideration as well as potential royalties and upfront payments declared directly strengthening corporation's balance sheet in terms of cash flow and marketable securities affecting the stock price.
10-11$ is a more accurate range for a probabale post-valuation according to the several analysts you mentionned, 28$ sounds too fun to be true but who knows ?
Biotech changes the way we perceive life,
Aljarar